213 related articles for article (PubMed ID: 34804072)
1. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.
Song A; Lin X; Lu J; Ren S; Cao Z; Zheng S; Hu Z; Li H; Shen C; Chen X
Front Immunol; 2021; 12():779347. PubMed ID: 34804072
[TBL] [Abstract][Full Text] [Related]
2. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
[TBL] [Abstract][Full Text] [Related]
3. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
4. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy.
Barone M; Iannone A; Di Leo A
World J Gastroenterol; 2014 Jul; 20(26):8722-5. PubMed ID: 25024631
[TBL] [Abstract][Full Text] [Related]
5. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
6. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis.
Zhang W; Xing M; Sun W; Chen J; Xie N; Cai Y; Wang Y; Li N; Jiang Y; Zhang F; Wang Y; Zeng Q; Ji Y; Xu C; Jiang C; Song J; Li G
J Viral Hepat; 2023 May; 30(5):427-436. PubMed ID: 36562258
[TBL] [Abstract][Full Text] [Related]
7. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
8. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.
Peng H; Wei F; Liu JY; Hu HD; Ren H; Hu P
Hepatol Int; 2015 Oct; 9(4):543-57. PubMed ID: 26162453
[TBL] [Abstract][Full Text] [Related]
9. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
[TBL] [Abstract][Full Text] [Related]
10. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
11. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance.
Qiu K; Liu B; Li SY; Li H; Chen ZW; Luo AR; Peng ML; Ren H; Hu P
Aliment Pharmacol Ther; 2018 May; 47(10):1340-1348. PubMed ID: 29577360
[TBL] [Abstract][Full Text] [Related]
12. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K
Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
14. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
15. Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers.
Li H; Lin X; Liu L; Qin L; Zheng Y; Liu X; Wei X; Liang S; Liu Y; Zhang J; Chen X; Cao Z
Front Immunol; 2022; 13():864354. PubMed ID: 35529845
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues.
Chen CH; Chiu YC; Lu SN; Lee CM; Wang JH; Hu TH; Hung CH
World J Gastroenterol; 2014 Jun; 20(24):7686-95. PubMed ID: 24976706
[TBL] [Abstract][Full Text] [Related]
17. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the therapeutic efficacy and factors influencing sequential combination of nucleos(t)ide analogues with pegylated interferon alpha for 48~96 weeks in the treatment of patients with chronic hepatitis B].
Jia R; Wang WX; Zhou ZP; Nie WM; Cheng YQ; Zhao J; Lian F; Luan JQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1290-1296. PubMed ID: 38253073
[No Abstract] [Full Text] [Related]
19. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
20. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
Li MH; Yi W; Zhang L; Lu Y; Lu HH; Shen G; Wu SL; Hao HX; Gao YJ; Chang M; Liu RY; Hu LP; Cao WH; Chen QQ; Li JN; Wan G; Xie Y
J Viral Hepat; 2019 Jul; 26 Suppl 1():32-41. PubMed ID: 31380582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
